J&J antes up on a $1B gam­ble that Ther­a­vance has the next block­buster JAK for Crohn’s, ul­cer­a­tive col­i­tis

Even as Gilead $GILD and Ab­b­Vie $AB­BV jock­ey for the lead in a com­pelling late-stage race to de­vel­op sys­temic JAK1 in­hibitors for in­flam­ma­to­ry bow­el dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA